
GOLD 2023 guidelines integrate exacerbation history, symptoms, and airflow limitation for initial management. Triple therapy (LABA/LAMA/ICS) benefits symptomatic patients, especially those with cardiovascular comorbidities or risk. An ABE+ classification proposes early triple therapy for such patients, based on evidence and clinician judgment.
Like
Save
Share